文献速递造血干细胞移植与细胞治疗白血病淋巴瘤

氟达拉滨/美法仑预处理下单倍体与单倍体-脐血移植比较

Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning.
PubMed 文献 · Blood Adv · 2019-01-01

在60岁以下成人中比较单倍体移植(haplo,170例)与单倍体-脐血移植(haplo-cord,137例)的结局,均接受氟达拉滨/美法仑减强度预处理。haplo-cord中性粒细胞和血小板恢复更快,急性和慢性GVHD更低,但两组总生存无显著差异。

要点

  • 4年OS:haplo-cord 50% vs haplo 49%;PFS:40% vs 45%,移植类型对OS、PFS无影响

核心结论

  • haplo与haplo-cord移植结局相似且令人鼓舞;haplo-cord中性粒细胞和血小板恢复更快、急性和慢性GVHD更低。
  • 多因素分析中移植类型对OS、PFS、复发和非复发死亡均无影响。

研究设计与样本

  • 回顾性研究,比较60岁以下成人单倍体移植170例(1个机构)与单倍体-脐血移植137例(2个机构)。
  • 所有患者接受氟达拉滨联合美法仑±全身照射的减强度预处理。

主要发现

  • 4年OS:haplo-cord组50% vs haplo组49%;PFS:haplo-cord组40% vs haplo组45%。

关键数值与推荐

  • haplo组GVHD预防为环磷酰胺、他克莫司和霉酚酸酯;haplo-cord组为抗胸腺细胞球蛋白、他克莫司和霉酚酸酯。
  • haplo移植主要使用骨髓,haplo-cord移植使用外周血干细胞。
  • haplo-cord组患者年龄更大且疾病更晚期。

临床怎么用

  • haplo-cord移植与更快的粒细胞和血小板恢复相关。
  • haplo-cord移植与更低的2-4级急性GVHD和1年慢性GVHD相关。
  • 两种移植类型在OS、PFS、复发和非复发死亡方面无显著差异。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Haplo-identical transplant with posttransplant cyclophosphamide (haplo) and umbilical cord blood transplant supported by third-party CD34 cells (haplo-cord) are competing approaches to alternative donor transplant. We compared, in adults younger than age 60 years, the outcomes of 170 haplo at 1 institution with that of 137 haplo-cord at 2 other institutions. All received reduced intensity conditioning with fludarabine and melphalan ± total body irradiation. GVHD prophylaxis for haplo consisted of cyclophosphamide, tacrolimus, and mycophenolate, whereas haplo-cord received antithymocyte globulin, tacrolimus, and mycophenolate. Haplo transplant used mostly bone marrow, and peripheral blood stem cells were used in haplo-cord transplants. Haplo-cord were older and had more advanced disease. Haplo-cord hastened median time to neutrophil (11 vs 18 days, P = .001) and platelet recovery (22 vs 25 days, P = .03). At 4 years, overall survival (OS) was 50% for haplo-cord vs 49% for haplo. Progression-free survival (PFS) was 40% for haplo-cord vs 45% for haplo. In multivariate analysis, the disease risk index was significant for OS (hazard ratio, 1.8; 95% confidence interval, 1.48-2.17; P = .00) and PFS. Total body irradiation was associated with decreased recurrence and improved PFS, age >40 with increased nonrelapse mortality. The type of transplant had no effect on OS, PFS, relapse, or nonrelapse mortality. Cumulative incidence of grade 2-4 acute graft-versus-host disease (GVHD) by day 100 was 16% after haplo-cord vs 33% after haplo (P < .0001), but grade 3-4 GVHD was similar. Chronic GVHD at 1 year was 4% after haplo-cord vs 16% after haplo (P < .0001). Haplo or haplo-cord results in similar and encouraging outcomes. Haplo-cord is associated with more rapid neutrophil and platelet recovery and lower acute and chronic GVHD. Institutional review board authorization for this retrospective study was obtained at each institution. Some patients participated in trials registered at www.clinicaltrials.gov as #NCT01810588 and NCT01050946.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. van Besien K, Artz A, Champlin RE, et al. Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Adv. 2019. PMID: 31217161. doi:10.1182/bloodadvances.2019000200

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。